Akashi Therapeutics now have the greenlight from the FDA to continue clinical development of HT-100. The biopharmceutical company is developing treatments for patients suffering from Duchenne muscular dystrophy (DMD). HT-100 (delayed-release halofuginone) development will continue under the new study name HALO-DMD-04. Following the clearance from the FDA, Marc Blaustein, Chief Executive Officer at Akashi Therapeutics […]
How far would you go for someone you love?
That’s the question that led to the birth of Jesse’s Journey when one family dared to dream about what’s possible after
learning the crushing news that Duchenne muscular dystrophy had become a part of their daily lives.
When John and Sherene Davidson learned that their middle son Jesse was diagnosed with Duchenne they charted a life
changing course for themselves-setting out to raise research funds to find the elusive cure.